Compare Biocon with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs NATCO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON NATCO PHARMA BIOCON /
NATCO PHARMA
 
P/E (TTM) x 40.3 45.8 88.0% View Chart
P/BV x 5.3 3.1 173.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 BIOCON    NATCO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-21
NATCO PHARMA
Mar-21
BIOCON /
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs488995 49.0%   
Low Rs275492 55.8%   
Sales per share (Unadj.) Rs59.2112.5 52.6%  
Earnings per share (Unadj.) Rs7.724.3 31.8%  
Cash flow per share (Unadj.) Rs13.730.7 44.6%  
Dividends per share (Unadj.) Rs05.25 0.0%  
Avg Dividend yield %00.7 0.0%  
Book value per share (Unadj.) Rs62.3225.1 27.7%  
Shares outstanding (eoy) m1,200.00182.34 658.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.46.6 97.4%   
Avg P/E ratio x49.430.6 161.3%  
P/CF ratio (eoy) x27.924.2 115.0%  
Price / Book Value ratio x6.13.3 185.3%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m457,350135,564 337.4%   
No. of employees `000NANA-   
Total wages/salary Rs m17,4104,149 419.6%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m71,05820,521 346.3%  
Other income Rs m6,0521,060 570.9%   
Total revenues Rs m77,11021,581 357.3%   
Gross profit Rs m13,1456,038 217.7%  
Depreciation Rs m7,1511,169 611.7%   
Interest Rs m577133 433.8%   
Profit before tax Rs m11,4695,796 197.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2151,372 161.4%   
Profit after tax Rs m9,2544,424 209.2%  
Gross profit margin %18.529.4 62.9%  
Effective tax rate %19.323.7 81.6%   
Net profit margin %13.021.6 60.4%  
BALANCE SHEET DATA
Current assets Rs m76,00423,373 325.2%   
Current liabilities Rs m42,1015,256 801.0%   
Net working cap to sales %47.788.3 54.0%  
Current ratio x1.84.4 40.6%  
Inventory Days Days13763 218.0%  
Debtors Days Days6373 85.2%  
Net fixed assets Rs m106,14224,546 432.4%   
Share capital Rs m6,000365 1,643.8%   
"Free" reserves Rs m68,72840,676 169.0%   
Net worth Rs m74,72841,041 182.1%   
Long term debt Rs m29,6169 329,066.7%   
Total assets Rs m182,14647,919 380.1%  
Interest coverage x20.944.6 46.8%   
Debt to equity ratio x0.40 180,725.1%  
Sales to assets ratio x0.40.4 91.1%   
Return on assets %5.49.5 56.8%  
Return on equity %12.410.8 114.9%  
Return on capital %11.514.4 79.9%  
Exports to sales %00-   
Imports to sales %7.210.9 65.8%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m5,0842,231 227.9%   
Fx inflow Rs m11,79111,194 105.3%   
Fx outflow Rs m5,0842,231 227.9%   
Net fx Rs m6,7078,963 74.8%   
CASH FLOW
From Operations Rs m11,5972,988 388.1%  
From Investments Rs m-36,247-1,033 3,508.9%  
From Financial Activity Rs m25,640-1,857 -1,380.7%  
Net Cashflow Rs m72360 1,205.0%  

Share Holding

Indian Promoters % 39.7 48.8 81.4%  
Foreign collaborators % 20.9 0.0 -  
Indian inst/Mut Fund % 24.0 28.1 85.4%  
FIIs % 15.6 11.9 130.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 51.2 76.9%  
Shareholders   347,911 85,828 405.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 24, 2022 03:31 PM

TRACK BIOCON

BIOCON - MESCO PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS